

December 3, 2021

Announcements

Dr. John Lewin Named Chief of Breast Imaging

On behalf of the Department of Radiology & Biomedical Imaging, we are delighted to announce that John M. Lewin, MD, FACR, will join Yale Cancer Center, Smilow Cancer Hospital, and Yale School of Medicine's Department of Radiology & Biomedical Imaging as Breast Imaging Division Chief.



Dr. Lewin completed his undergraduate and medical education at Harvard University followed by residency and breast imaging fellowship at the University of Colorado Health Sciences Center. He remained in Colorado, working successfully in both academic and private practice settings. He has served on many national radiology committees including the American College of Radiology Imaging Network (ACRIN) Working Group on Digital Mammography, the American College of Radiology (ACR) Breast MRI Lexicon Working Group, and the ACR Contrast Mammography BI-RADS Group. He is currently the Vice President for the Society of Breast Imaging (SBI) and will serve as SBI President in 2022.

Dr. Lewin has funded research related to image processing/advancing technical innovations in breast imaging, including contrast-enhanced mammography and cancer laser ablation techniques. He has also won several research awards during his career.

Dr. David Braun Joins CMCO

David Braun, MD, PhD, has been appointed an Assistant Professor of Medicine (Medical Oncology) and joins the Center of Molecular and Cellular Oncology (CMCO) at

Yale Cancer Center. Dr.




from the desk of
Nita Ahuja, MD, MBA, FACS
Interim Director, Yale Cancer Center
Interim Physician-in-Chief,
Smilow Cancer Hospital

Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center

A 45-year Legacy of Research and
Collaboration



[Read More](#)

Braun cares for patients with kidney cancers. He received his PhD in Computational Biology from the Courant Institute of Mathematical Science at New York University and his medical degree from Icahn School of Medicine at Mount Sinai. He completed his residency at the Brigham and Women's Hospital where he received the Dunn Medical Intern Award and served as Chief Medical Resident before completing fellowship training in adult oncology through the Dana-Farber/Partners CancerCare program where he was appointed the Emil Frei Fellow and the John R. Svenson Fellow.



Dr. Braun joins Yale from Dana-Farber Cancer Institute where he was an Instructor in Medicine with clinical and scientific interest in understanding and improving immune therapies for kidney cancer. He has a longstanding interest in integrating experimental and computational approaches to biomedical research and is currently studying mechanisms of response and resistance to immune therapy in kidney cancer, with the goal of developing novel therapies. He will continue this work as part of the CMCO, which fosters and mentors physician-scientists as they advance their laboratory-based research programs to bridge fundamental cancer biology with clinical investigation for the translation of basic discoveries into better treatments or diagnosis.

Dr. Braun joins Yale from Dana-Farber Cancer Institute where he was an Instructor in Medicine with clinical and scientific interest in understanding and improving immune therapies for kidney cancer. He has a longstanding interest in integrating experimental and computational approaches to biomedical research and is currently studying mechanisms of response and resistance to immune therapy in kidney cancer, with the goal of developing novel therapies. He will continue this work as part of the CMCO, which fosters and mentors physician-scientists as they advance their laboratory-based research programs to bridge fundamental cancer biology with clinical investigation for the translation of basic discoveries into better treatments or diagnosis.

Yale Cancer Center Research at National Meetings

Our Hematology and Breast Cancer teams will close out a busy year with participation in annual meetings in December. Beginning December 8, our Hematology Program will participate in the 63rd American Society of Hematology (ASH) Annual Meeting with presentations on clinical and research advances for the treatment of hematologic malignancies. In addition, our Breast Cancer team will participate in the annual San Antonio Breast Cancer Symposium (SABCS) starting on December, 7. Please review the presentations from Yale scheduled to be presented at **ASH** and **SABCS** and support your colleagues during their hybrid presentations.


Notables

Stacey Stein, MD, Associate Professor of Medicine (Medical Oncology), has been selected to participate in the Yale New Haven Health Institute of Excellence 2021-22 **Lean in Circle**. The program provides women leaders with the opportunity to speak openly about the challenges faced in the workforce, foster mentorship, engage in shared problem solving and empower the pursuit of professional achievements.

Eric Song, a sixth-year MD/PhD student in the laboratory of **Akiko Iwasaki, PhD**, Waldemar Von Zedtwitz Professor of Immunobiology, Professor of


Molecular, Cellular and Developmental Biology and of Epidemiology (Microbial Diseases), and a member of Yale Cancer Center's Cancer

Less Restrictive Health Laws Linked to Higher HPV Vaccination Rates




[Read More](#)

Pathologist Robert Homer, MD, PhD, on Lung Cancer Awareness Month



[Read More](#)

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatments



[Read More](#)

Early Detection Research at Yale Cancer Center Could be a Game Changer for Hard to Diagnose Pancreatic Cancer

Immunology Research Program, is a member of this year's **STAT Wunderkinds** cohort. STAT Wunderkinds celebrates early-career researchers. Eric has been actively engaged in research since his junior year in college, with 23 publications before he started his graduate program at Yale. He now has spent nearly a decade developing with therapies for brain tumors and has co-authored close to 60-peer reviewed articles.

Prasanna Ananth, MD, MPH, Assistant Professor of Pediatrics (Hematology/Oncology) and a member of Yale Cancer Center's Cancer Prevention and Control Research Program, has been elected to membership in the **Society for Pediatric Research**.

Sajid A. Khan, MD, Associate Professor of Surgery (Surgical Oncology) and a member of Yale Cancer Center's Genetics, Genomics, and Epigenetics Research Program, has been appointed to the editorial board in the Translational Research Section of the **Annals of Surgical Oncology**.

Aaron Ring, MD, PhD, Assistant Professor of Immunobiology and a member of Yale Cancer Center's Cancer Immunology Research Program, has been named to *Nature Biotechnology's* list of **"Top 20 Translational Researchers of 2020,"** which recognizes success in patenting.

Patricia LoRusso, DO, Professor of Medicine (Medical Oncology) and Associate Cancer Center Director for Experimental Therapeutics, has been named **Chair of the American Association for Cancer Research (AACR) KRAS Task Force** to lead the AACR KRAS Symposium in 2022.

Valentina Greco, PhD, Carolyn Walch Slayman Professor of Genetics and a member of Yale Cancer Center's Cancer Signaling Networks Research Program, is president-elect of the **Society for Investigative Dermatology** for 2021-22. Dr. Greco takes office as president next year.

Caro Kravitz, a fourth-year graduate student in the laboratory of **Don Nguyen, PhD**, has been awarded a **F31 grant** to support her project, "Determining the Molecular Contributions of KDM2A in NSCLC Metastasis." Caro is studying the mechanism by which a specific epigenetic modifier, KDM2A, contributes to the metastatic capacity of KRAS mutant Non-Small Cell Lung Cancer.

Matt Murray, a fourth-year PhD candidate in the laboratory of **Ranjit Bindra, MD, PhD**, has been awarded a **F31 Diversity Grant** to support a collaborative project with the laboratory of **W. Mark Saltzman, PhD**, to study gliomas. Specifically, he is looking to develop and utilize nanoparticle-encapsulated inhibitors for the treatment of diffuse intrinsic pontine glioma (DIPG) with high efficacy and low toxicity.


The **Institute for Scientific Information** has named 26 Yale School of Medicine faculty members, including 15 members from Yale Cancer Center, among 2021's most influential scientists based on citations to their publications from 2010 to 2020. The Institute recognizes true pioneers in their fields, demonstrated by the production of multiple highly cited papers that rank in the top 1% by citations for field and year in the Web of Science™. Of the world's scientists and social scientists, Highly Cited Researchers are one in 1,000. Yale Cancer Center members recognized include:

NOVEMBER IS
PANCREATIC CANCER
AWARENESS MONTH




[Read More](#)

Yale Cancer Center Experts Co-Author Book on War on Cancer




[Read More](#)

Smilow Shares: Lung Cancer Awareness Month



[Watch Now](#)


Smilow Shares: World Pancreatic Cancer Day



[Watch Now](#)

GI Pathologist Dr. Marie Robert:

Pancreatic Cancer Awareness Month



Craig Crews, PhD, John C. Malone Professor of Molecular, Cellular, and Developmental Biology and Professor of Chemistry, of Pharmacology, and of Management; Executive Director, Yale Center for Molecular Discovery
Lieping Chen, MD, PhD, United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology); Co-Leader, Cancer Immunology Research Program, Yale Cancer Center

Mark Gerstein, PhD, Albert L Williams Professor of Biomedical Informatics and Professor of Molecular Biophysics & Biochemistry, of Computer Science, and of Statistics & Data Science

Scott Gettinger, MD, Professor of Internal Medicine (Medical Oncology); Chief, Thoracic Medical Oncology

Andrew Goodman, PhD, C.N.H. Long Professor of Microbial Pathogenesis and Director of Microbial Sciences Institute

David A. Hafler, MD, FANA, William S. and Lois Stiles Egerly Professor of Neurology and Professor of Immunobiology; Chair, Department of Neurology; Neurologist-in-Chief, Yale New Haven Hospital

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science

Silvio Inzucchi, MD, Professor of Medicine (Endocrinology)

Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Professor of Immunobiology; Professor of Molecular, Cellular and Developmental Biology; Professor of Epidemiology (Microbial Diseases); Professor of Molecular Cellular and Developmental Biology; Investigator, Howard Hughes Medical Institute

Grace Kong, PhD, Assistant Professor of Psychiatry

Suchitra Krishnan-Sarin, PhD, Professor of Psychiatry; Chair, Human Investigations Committee (IRB), Human Research Protections Program

Ruslan Medzhitov, PhD, Sterling Professor of Immunobiology; Investigator, Howard Hughes Medical Institute

David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and Professor of Medicine (Medical Oncology); Director, Yale Cancer Center Tissue Microarray Facility, Pathology; Director, Yale Pathology Tissue Services, Pathology; Director, Physician Scientist Training Program, Pathology Research


Gerald Shulman, MD, PhD, George R. Cowgill Professor of Medicine (Endocrinology) and Professor of Cellular and Molecular Physiology; Co-Director, Yale Diabetes Research Center, Internal Medicine

Mario Sznol, MD, Professor of Medicine (Medical Oncology); Co-Leader, Cancer Immunology Research Program, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

The Cancer Signaling Network Research Program

welcomes **Won Jae Huh, MD, PhD**, Assistant Professor of Pathology. Dr. Huh is a physician-scientist with clinical expertise in Gastrointestinal Pathology.

His laboratory work is focused on signaling mechanisms involved including EGFR and NOTCH



I want our patients and families to know how dedicated we are to helping them using the tools we have now. But I also want them to understand that we are working tirelessly to find better answers for the future."

MARIE ROBERT, MD
Director, Gastrointestinal and Liver Pathology




YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated by the National Cancer Institute

[Read More](#)



Join Smilow Cancer Hospital on Facebook



Finding things to be thankful for during challenging times is not always easy. This mother and daughter nursing duo at the Smilow Cancer Hospital Care Center in Guilford reunited during COVID to care for our patients with cancer. In honor of the Thanksgiving holiday, they share their story of togetherness and love.

"NEVER IN MY LIFE WOULD I HAVE IMAGINED BEING ABLE TO REUNITE WITH MY DAUGHTER AT WORK DURING COVID! WE TOOK GREAT DELIGHT IN DOING A SELFIE ON OUR BREAK DURING OUR FIRST DAY OF WORK TOGETHER IN GUILFORD...I WILL CHERISH EVERY DAY THAT I AM ABLE TO WORK WITH MY DAUGHTER, WHO IS AN AMAZING NURSE."
-CAROL PHILIPS, RN



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated by the National Cancer Institute

[Read More](#)

Riley Norwood (l) and Alyssa Milburn (r) teamed up with their school Mount Saint Mary College in Newburgh, NY, the Student

signaling in gastric pre-malignant disease. Dr. Huh's contribution in the field of gastric physiology and pathophysiology includes elucidating the role of transcription factor XBP1 in the differentiation of the gastric chief cell lineage, the development of a spasmodic polypeptide-expressing metaplasia (SPEM) mouse model, demonstration of the genotoxicity of tamoxifen-inducible Cre recombinase, CreERT2, characterization of novel EGFR reporter mouse line, EgfrEmeraldGFP (Em), and first available neutralizing antibodies, P1X and P2X, to mouse EGFR.



Diversity, Equity, and Inclusion

The National Institutes of Health (NIH) launched the **UNITE initiative** in March of 2021 to address structural racism in the biomedical research enterprise. Through this initiative, the NIH is holding a series of listening sessions and welcomes your attendance to share full range of issues and challenges in advancing racial and ethnic equity in the biomedical research enterprise. Some of these issues include:


- Changing culture to promote equity, inclusivity, and justice
- Improving policies, transparency, and oversight
- Strengthening career pathways, training, mentoring, and the professoriate
- Ensuring fairness in review and funding deliberations
- Enhancing funding and research support for diverse institutions and historically under-resourced research areas
- Structural racism in the biomedical research enterprise

The insights shared during these **listening sessions** will help to identify priorities for UNITE and inform the development of an NIH action plan. If interested, please **register** to join an upcoming session.

Employee Profile: Sylvia Lempit

Sylvia Lempit, APRN with the Smilow Liver Cancer Program, is a rare gem according to Dr. Mario Strazzabosco, Professor of Medicine and Clinical Program Leader of the Liver Cancer Program. "She specializes in liver disease, liver cancer, and liver transplant, which is a unique combination that you don't find everywhere."

When Sylvia joined Yale in 2006, it was a second career for her. After working in human



Mary College in Newburgh, NY, and the Student Nurses Association and the Student Government to raise support for the Smilow Breast Cancer Program through fundraising and raffles at their Pink Out soccer games. This effort is greatly appreciated and we applaud these wonderful ladies!



[Read More](#)

Do you currently smoke cigarettes? You may be eligible for a paid Yale University study investigating alternative nicotine products. Click the link below or call/text 203-464-7850 for more information. All calls are confidential.



[Read More](#)

It's #GivingTuesday! All donations made to

Closer to Free support Smilow Cancer Hospital and Yale Cancer Center's mission to pursue the latest advances in cancer research at Yale Cancer Center, develop promising new cancer treatments, and make

resources and taking time off to raise her family, she decided to become an EMT and go back to school full-time. She graduated from Yale School of Nursing and then completed a year-long fellowship funded by the American Association for the Study of Liver Disease (AASLD) Foundation. In her current role with the Liver Cancer Program, which she joined in 2016, Sylvia sees patients in New Haven and at a pre-care clinic in Bridgeport where she cares for underserved patients with liver abnormalities. A very important component of her work is getting patients treatment for Hepatitis C virus and access into the health care system. She also provides counseling and meets with patients to assess their liver function and help plan next steps. Although she does not administer therapies, she works closely with Medical Oncology, Interventional Oncology, and Surgical Oncology while patients are undergoing treatment to help maintain liver function.



Sylvia follows patients from the time of diagnosis until it is time to transition to palliative or hospice care. “Patients with liver disease run the gamut, and I have pretty much seen it all,” said Sylvia. “Once therapy to treat their cancer is no longer recommended, I continue to monitor liver function and provide interventions and resources to keep them as stable as possible for as long as possible. Patients and their families are so appreciative of this extra support we provide.”

Sylvia has patients that were diagnosed years ago, and she still follows them very closely; in fact, the follow-up and surveillance is so rigorous that often other cancers and diseases are found. As this patient population is at high-risk for complications from COVID-19 infection, a lot of her time is also spent educating them on the importance of getting the COVID-19 vaccine.

Recent Publications

K. Kalinsky, W.E. Barlow, J.R. Gralow, F. Meric-Bernstam, K.S. Albain, D.F. Hayes, N.U. Lin, E.A. Perez, L.J. Goldstein, S.K.L. Chia, S. Dhesy-Thind, P. Rastogi, E. Alba, S. Delaloge, M. Martin, C.M. Kelly, M. Ruiz-Borrego, M. Gil-Gil, C.H. Arce-Salinas, E.G.C. Brain, E.-S. Lee, J.-Y. Pierga, B. Bermejo, M. Ramos-Vazquez, K.-H. Jung, J.-M. Ferrero, A.F. Schott, S. Shak, P. Sharma, D.L. Lew, J. Miao, D. Tripathy, L. Pusztai, and G.N. Hortobagay
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

N Engl J Med 10.1056/NEJMoa2108873

[Read More](#)

Gilani SM, Abi-Raad R, Garritano J, Cai G, Prasad ML, Adeniran AJ.
RAS Mutation and Associated Risk of Malignancy In The Thyroid Gland: An FNA Study With Cytology-Histology Correlation
Cancer Cytopathology, Online ahead of print.

[Read More](#)

promising new cancer treatments, and make these therapies available as quickly as possible to our patients at Smilow Cancer Hospital.

give
closer to free
Help advance cancer research and enhance patient care.

Yale
NewHaven
Health
Smilow Cancer
Hospital



The Smilow Cancer Hospital and Yale Cancer Center Closer to Free Fund

[Read More](#)

Early detection helps identify lung cancer for effective treatment. Did you know that five-year cure rates for early lung cancer are as great as 85 percent?

The Smilow Cancer Hospital Lung Cancer Screening Program includes a comprehensive multidisciplinary team of internationally recognized pulmonologists, chest radiologists, thoracic surgeons, thoracic oncologists, tobacco treatment specialists, and nurse practitioners. Our Program provides: personalized lung cancer risk evaluation; detailed discussion of an individual's benefits and downsides of lung screening; smoking cessation counseling and treatment for active smokers; low dose screening CT scan or other tests, if indicated; CT scan review and interpretation by a dedicated and experienced team; management recommendations of any findings from our expert panel; and continuity of care and ongoing monitoring.

Lung Screenings Save Lives

Lung cancer is by far the leading cause of cancer related deaths. Lung screening with CT scans can save lives by identifying lung cancer early.

[Read More](#)

Robert SM, Vetsa S, Nadar A, Vasandani S, Youngblood MW, Gorelick E, Jin L, Marianayanam N, Erson-Omay EZ, Günel M, Moliterno J.

The Integrated Multiomic Diagnosis Of Sporadic Meningiomas: A Review Of Its Clinical Implications

Journal of Neuro-Oncology, Online ahead of print.

[Read More](#)

Beroukhim G, Ozgediz D, Cohen PJ, Hui P, Morotti R, Schwartz PE, Yang-Hartwich Y, Vash-Margita A.

Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review

Journal of Pediatric and Adolescent Gynecology, Online ahead of print.

[Read More](#)

Marsden CG, Das L, Nottoli TP, Kathe SD, Doublie S, Wallace SS, Sweasy JB.

Mouse Embryonic Fibroblasts Isolated From Nth1 D227Y Knockin Mice Exhibit Defective DNA Repair and Increased Genome Instability

DNA Repair, Online ahead of print.

[Read More](#)

Li T, Stayrook SE, Tsutsui Y, Zhang J, Wang Y, Li H, Proffitt A, Krimmer SG, Ahmed M, Belliveau O, Walker IX, Mudumbi KC, Suzuki Y, Lax I, Alvarado D, Lemmon MA, Schlessinger J, Klein DE.

Structural Basis For Ligand Reception By Anaplastic Lymphoma Kinase

Nature, Online ahead of print.

[Read More](#)

Shin JH, Jeong J, Maher SE, Lee HW, Lim J, Bothwell ALM.

Colon Cancer Cells Acquire Immune Regulatory Molecules From Tumor-Infiltrating Lymphocytes By Trogocytosis

Proceedings of the National Academy of Sciences, 118(48):e2110241118

[Read More](#)

Chhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, Sharma A, Ahuja N, Kastrinos F, Farrell JJ.

Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis

Gastroenterology, Online ahead of print.

[Read More](#)

Barak T, Vetsa S, Nadar A, Jin L, Gupte TP, Fomchenko EI, Miyagishima DF, Yalcin K, Vasandani S, Gorelick E, Zhao AY, Antonios J, Theriault BC, Lifton N, Marianayagam N, Omay B, Omay ZE, Huttner A, McGuone D, Blondin NA, Corbin Z, Fulbright RK, Moliterno J.

Correction to: Surgical Strategies For Older Patients With Glioblastoma


Journal of Neuro-Oncology, Online ahead of print.

[Read More](#)

Park JJ, Chen S.

Metaviromic Identification Of Discriminative Genomic Features In SARS-Cov-2 Using Machine Learning

Patterns, Online ahead of print



YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

[Read More](#)

During #lungcancerawarenessmonth, Dr. Thomas Hayman asks us to pause and remember, "the patients, families, and caregivers who have been through a diagnosis of lung cancer, as this is an incredibly difficult disease and through their selfless participation in clinical trials, we continue to advance treatment options."



[Read More](#)

Lindsay's Legacy Foundation was founded in 2019 to honor the life of Lindsay Presz Barrett. The organization was formed by Lindsay's family to remember Lindsay, her journey and her profound message of HOPE. Their August 2021 Be Happy Run/Walk in Windsor once again raised generous support for Dr. Amer Zeidan's work in clinical trials for Acute Myeloid Leukemia (AML). We are grateful to this extraordinary family for their continued focus on our work and on our patients! Pictured (l to r) Lindsay's mother Carla Presz, Dr. Amer Zeidan, and Lindsay's sister and brother-in-law Stephanie and TJ McKenna.

attempts, Online ahead of print.

[Read More](#)

Koelmel JP, Tan WY, Li Y, Bowden JA, Ahmadireskety A, Patt AC, Orlicky DJ, Mathé E, Kroeger NM, Thompson DC, Cochran JA, Golla JP, Kandyliari A, Chen Y, Charkoftaki G, Guingab-Cagmat JD, Tsugawa H, Arora A, Veselkov K, Kato S, Otoki Y, Nakagawa K, Yost RA, Garrett TJ, Vasilou V.

Lipidomics and Redox Lipidomics Indicate Early Stage Alcohol-Induced Liver Damage

Hepatology Communications, Online ahead of print.

[Read More](#)

Wancata LM, Billingsley KG, Paillet J, Mayo SC, Sheppard BC, Hansen L.

The Patient's Perspective: A Qualitative Study Of Individual Experience With Decision-Making, Treatment, And Recovery For Resectable Pancreatic Cancer

Supportive Care in Cancer, Online ahead of print.

[Read More](#)

Lee V, An Y, Park HS, Yu JB, Kim SP, Jairam V.

Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History

BJU International, Online ahead of print.

[Read More](#)

Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasti A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, Saad F, Petrylak DP, Pachynski RK.

Nivolumab Plus Docetaxel In Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Results From The Phase II Checkmate 9KD Trial

European Journal of Cancer, Online ahead of print.

[Read More](#)

Yang Sun T, Hwang G, Pancirer D, Hornbacker K, Codima A, Lui NS, Raj R, Kunz P, Padda SK.

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Clinical Characteristics And Progression To Carcinoid Tumor

European Respiratory Journal, Online ahead of print.

[Read More](#)

Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L.

The Neglected Role of Bile Duct Epithelial Cells in NASH

Seminars in Liver Disease, Online ahead of print.

[Read More](#)

Burtness, B.

A commentary on: Hypoxia-Guided Therapy for Head and Neck Cancers

Practice Update Website.

[Read More](#)

Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F,



[Read More](#)

Follow Yale Cancer Center on Twitter

[Follow us on twitter](#)



“Recommended screening significantly reduces cancer-related deaths; the numbers are astounding.”
— Dr. Xavier Llor, @NCCN panel Vice-Chair on new patient screening guidelines for #colorectalcancer.



New practice changing #breastcancer data from the RxPonder study with Dr. Lajos Pustzai & colleagues nationwide shows chemoendocrine therapy had longer disease-free survival in premenopausal women v. endocrine-only therapy.



Tune in as @AnneChiangMD provides expert analysis and summaries of key studies presented at #WCLC21.



Join us at 12pm today for grand rounds presented by Dr. Omar Abdel-Wahab @AbdelWahablab

@sloan_kettering who will give the Blanche Tullman Lectureship in #Hematology on "Novel Targeted Therapeutics for #Leukemia."



“Maybe a 70-year-old of the future will look more like a 40 or 50-year-old of today.” @DrMorganQuinn discussed

Dang TS, Hour TS, Kim WS, Santana-Davia R, Panning T, Squimier T, Sun T, Kuo TC, Wan HJ, Pons J, Randolph SS, Messersmith WA.

Evorpcept Alone And In Combination With Pembrolizumab Or Trastuzumab In Patients With Advanced Solid Tumours (ASPEN-01): A First-In-Human, Open-Label, Multicentre, Phase 1 Dose-Escalation And Dose-Expansion Study

Lancet Oncology, Online ahead of print.

[Read More](#)

Strosberg JR, Caplin ME, Kunz PL, Ruzsiewicz PB, Bodei L, Hendifar A, Mitra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators.

¹⁷⁷Lu-Dotatate Plus Long-Acting Octreotide Versus High-Dose Long-Acting Octreotide In Patients With Midgut Neuroendocrine Tumours (NETTER-1): Final Overall Survival And Long-Term Safety Results From An Open-Label, Randomised, Controlled, Phase 3 Trial

Lancet Oncology, Online ahead of print.

[Read More](#)

Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D.

Incidence, Risk Factors, And Mortality Of Atrial Fibrillation In Breast Cancer: A SEER-Medicare Analysis

European Heart Journal, Online ahead of print.

[Read More](#)

Clark M, Kollara A, Brown TJ, May T.

A Mouse Model Of Neoadjuvant Chemotherapy Followed By Interval Cytoreductive Surgery Indicates Impaired Efficacy Of Perioperative Cisplatin

Journal of Ovarian Research, 14(1):157.

[Read More](#)

Fisk JN, Mahal AR, Dornburg A, Gaffney SG, Aneja S, Contessa JN, Rimm D, Yu JB, Townsend JP.

Premetastatic Shifts Of Endogenous And Exogenous Mutational Processes Support Consolidative Therapy In EGFR-Driven Lung Adenocarcinoma

Cancer Letters, Online ahead of print.

[Read More](#)

Chen PH, Hu Z, An E, Okeke I, Zheng S, Luo X, Gong A, Jaime-Figueroa S, Crews CM.

Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)

ACS Chemical Biology, Online ahead of print.

[Read More](#)

Wagner GP, Kshitiz, Dighe A, Levchenko A.

The Coevolution of Placentation and Cancer

Annual Review of Animal Biosciences, Online ahead of print.

[Read More](#)

Torres AR, Johnson NP, Ellingson MK, Hansen CE, Oliveira CR, Niccolai LM, Sboth SS

her cutting-edge aging/epigenetic clock research w/@RealJanePauley in @CBSSunday prime-time special.



The @AmericanCancer has renewed its Institutional Research Grant to @YaleCancer led by Dr. Daniel DiMaio. Our annual award has been funded for 40+ years, having a impact launching the careers of junior faculty, including promotion, awards, & pubs.



New research led by HenryParkMD in Advances in Radiation Oncology @ASTRO_org highlights barriers to #radiationoncology treatment in underserved communities & possible approaches overcoming obstacles.



New research led by AneesChagpar in @SESC_AmSurg shows preoperative MRI significantly increases time to surgery for patients with #breastcancer & suggests surgeons should consider this factor before ordering.



Exciting research led by Drs. Joseph Schlessinger & Daryl Klein in @Nature reveals the receptor structure of the molecule anaplastic lymphoma kinase, opening paths for #cancer treatment development.



Congrats to Nicole Deziel, PhD @DezielLab_Yale awarded @American Cancer Research Scholar Grant to study assoc. of early exposure to environmental thyroid hormone disrupting chemicals w/peds. thyroid cancer.



In a new meta-analysis led by @JamesFarrellGI in @AGA_Gastro, late-stage pancreaticcancer was detected during surveillance for high-risk patients, but lacked association with clinicoradiologic features.



"Cancer care and research can be intense, both intensely meaningful and intensely hard, and that is why I love it: because my work matters." LauraVanBaum honors PancreaticCancerAwarenessMonth.



Sheth SS.

State Laws Permitting Adolescent Consent to Human Papillomavirus Vaccination and Rates of Immunization

JAMA Pediatrics, Online ahead of print.

[Read More](#)

Kim, PL.

Targeting Gene Fusions In Glioma

Current Opinion in Neurology, 34(6):840-847.

[Read More](#)

Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans WF, Geyer CE Jr, Loibl S, Stover DG.

Matched Cohort Study Of Germline BRCA Mutation Carriers With Triple Negative Breast Cancer In Brightness

NPJ Breast Cancer, 7(1):142.

[Read More](#)

Contreras-Trujillo H, Eerdeng J, Akre S, Jiang D, Contreras J, Gala B, Vergel-Rodriguez MC, Lee Y, Jorapur A, Andreasian A, Harton L, Bramlett CS, Nogalska A, Xiao G, Lee JW, Chan LN, Mutschen M, Merchant AA, Lu R.

Deciphering Intratumoral Heterogeneity Using Integrated Clonal Tracking And Single-Cell Transcriptome Analyses

Nature Communications, 12(1):6522.

[Read More](#)

Marks VA, Hsiang WR, Umer W, Haleem A, Leapman MS, Kunstman JW, Schuster KM.

Access to Colorectal Cancer Care for Medicaid-Insured Patients at Designated Cancer Facilities

Annals of Surgical Oncology, Online ahead of print.

[Read More](#)

Ermer T, Walters SL, Canavan ME, Salazar MC, Li AX, Doonan M, Boffa DJ.

Understanding the Implications of Medicaid Expansion for Cancer Care in the US: A Review

JAMA Oncology, Online ahead of print.

[Read More](#)

Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X.

Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening

JAMA Oncology, Online ahead of print.

[Read More](#)

Olawoyin OM, Mehta S, Chouairi F, Gabrick KS, Avraham T, Pusztai L, Alperovich M.

Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen

Plastic and Reconstructive Surgery, 148(6):1186-1196.

[Read More](#)



#WorldPancreaticCancerDay is

today! Dr. @JamesFarrellGI shares

his thoughts on the future of pancreatic cancer and his research into early detection and prevention.



Thank you to our Center for thoracic

Cancers @SmilowCancer team for

a fantastic Smilow Shares presentation in honor of [#LungCancerAwarenessMonth](#)

Calendar

Yale Cancer Answers

December 5; 7:30 PM

NPR

Advances in Colon and Rectal Surgery

Ira Leeds, MD, MBA, ScM

[Learn More](#)

Radiobiology and Genome Integrity Research Program

December 6; 11:00 AM

Are Cancers Addicted to Aneuploidy?

Jason Sheltzer, PhD

[Learn More](#)

Cognitive Behavioral Therapy: Skills Group for Cancer Survivors

December 6, 2:30 PM

[Learn More](#)

Yale Cancer Center Grand Rounds

December 7; 12:00 PM

Management of Spinal Tumors and New

Directions in Lung Stereotactic Body

Radiotherapy

Ehud Mendel, MD, MBA and Henry S. Park,

MD, MPH

[Learn More](#)

Yale Center for Immuno-Oncology Seminar (presented as part of the Human and Translational Immunology Program

Seminar Series)

December 7, 4:00 PM

Cell Therapies for Cancer – Beyond CARs

Catherine Bollard, MD, MBChB

[Learn More](#)

Pathology Grand Rounds

December 9; 12:30 PM

Race in Medicine: Data or Distraction?

Andrea Dupont, MD, PhD and Joseph

Omuro, A.

Editorial: Advances In Neuro-Oncology: Stepping In The Right Direction

Current Opinion in Neurology, 34(6):825-826.

[Read More](#)

Pak LM, Purad CC, Nadipally S, Rao MP, Mukherjee S, Hegde SKB, Golshan M.

ASO Visual Abstract: Cancer Awareness and Stigma in Rural Assam India: Baseline Survey of the Detect Early and Save Her/Him (DESH) Program

Annals of Surgical Oncology, 28(Suppl 3):727-728.

[Read More](#)

Bewersdorf JP, Patel KK, Huntington SF, Zeidan AM.

Cost-effectiveness Analysis Of Oral Azacitidine Maintenance Therapy In Acute Myeloid Leukemia

Blood Advances, 5(22):4686-4690.

[Read More](#)

Shammas RL, Fish LJ, Sergesketter AR, Offodile AC 2nd, Phillips BT, Oshima S, Lee CN, Hollenbeck ST, Greenup RA.

ASO Visual Abstract: Dissatisfaction After Post-Mastectomy Breast Reconstruction: A Mixed-Methods Study

Annals of Surgical Oncology, 28(Suppl 3):720-721

[Read More](#)

Funding and Award Opportunities

HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)

The purpose of this FOA is to solicit applications to accelerate development, testing and implementation of evidence-based interventions—that are culturally and linguistically appropriate for NIH-designated populations that experience health disparities in the United States—to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes.

Application Deadline: December 9, 2021

[Read More](#)

ASCO Women Who Conquer Cancer Mentorship Awards

The awards recognize extraordinary women leaders in oncology and role models who have excelled as a mentor and have demonstrated outstanding

commitment to the professional development of women colleagues as clinicians, educators, and researchers in oncology.

Application Deadline: December 10, 2021

[Read More](#)

The Conquer Cancer – Breast Cancer Research Foundation Research Professorship for Diversity and Inclusion in Breast Cancer

Provides flexible funding to outstanding researchers who have made, and are continuing to make, significant contributions in breast cancer research and will dedicate their time in training future breast cancer researchers.

Letter of Intent Due December 14, 2021

Andrea Deyrup, MD, PhD and Joseph L.

Graves, Jr., PhD

[Learn More](#)

Cancer Genetics and Prevention Seminar

December 9; 2:30 PM

Journal Club - GINA and Beyond: The Realities of Genetic Discrimination

Alexandra McClellan, MS, CGC

[Learn More](#)

Center for GI Cancers Journal Club

December 9; 4:15 PM

Rectal Cancer TBD

Ira Leeds, MD, MBA, ScM

[Learn More](#)

Yale Cancer Answers

December 12; 7:30 PM

NPR

Genomic Causes of Cancer Progression and Therapeutic Vulnerability

Jason Sheltzer, PhD

[Learn More](#)

Yale Cancer Center Seminar

December 13; 12:00 PM

Evaluating the Immune Modulating Effects of MEK and Autophagy Inhibition in Pancreas Cancer Using Patient Derived Organoids and Co-culture Model

Winston Wong, MD

[Learn More](#)

Division of Reproductive Sciences

Special Seminar

December 13; 12:00 PM

Improving Treatment Responses in Gynecologic Cancers

Katherine Fuh, MD, PhD

[Learn More](#)

Yale Pancreatic Cancer Collaborative Seminar Series

December 13; 2:00 PM

Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment

Mara Sherman, PhD

[Learn More](#)

Cognitive Behavioral Therapy: Skills Group for Cancer Survivors

December 13, 2:30 PM

[Learn More](#)

Cognitive Behavioral Therapy for Cancer Survivors

Letter of Intent Due: December 14, 2021

[Read More](#)

The Conquer Cancer – Breast Cancer Research Foundation Advanced Clinical Research Award (ACRA) for Diversity and Inclusion in Breast Cancer Research

Designed with the primary goal of increasing diversity in the oncology workforce and cancer research. Awards will be given to mid-career investigators who are members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research, and who wish to conduct original breast cancer research not currently funded.

Letter of Intent Due: December 14, 2021

[Read More](#)

HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3)

The purpose of this FOA is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care.

Application Deadline: December 15, 2021

[Read More](#)

HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3)

The purpose of this FOA is to solicit cooperative agreement applications to support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed.

Application Deadline: December 15, 2021

[Read More](#)

Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01)

The purpose of this FOA is to support and accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

Application Deadline: December 15, 2021

[Read More](#)

Alex's Lemonade Stand Foundation (ALSF) and RUNX1 Early Career Investigator Grant

The purpose of this grant is to promote the establishment of a new generation of translational and clinical researchers interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder.

Application Deadline: December 20, 2021

[Read More](#)

Genetics Department Seminar Series

December 14, 11:30 AM

Todd Macfarlan, PhD

[Learn More](#)

Yale RNA Club

December 14; 8:45 AM

[Learn More](#)

Yale Cancer Center Grand Rounds

December 14; 12:00 PM

Matthew Rodeheffer, PhD

[Learn More](#)

Human and Translational Immunology Seminar Series:

December 14; 4:00 PM

Translational Research In Parasite Biology: Skating To Where The Puck Is Going

Choukri Ben Mamoun, PhD

[Learn More](#)

Yale Cancer Biology Institute/Center for Molecular and Cellular Oncology Seminar

December 14, 4:00 PM

Condensation of TDP-43 Selectively Contributes To Its RNA Binding And Function Across The Transcriptome

Jernej Ule, PhD

[Learn More](#)

Yale Head and Neck SPORE's Monthly Meeting

December 15; 6:00 PM

[Learn More](#)

Pathology Grand Rounds

December 16; 12:30 PM

T Cell Role in the Pathophysiology of Heart Failure

Pilar Alcaide, PhD

[Learn More](#)

Yale Cancer Center Seminar

December 16; 1:00 PM

Building The Bridge: Connecting Diversity, Equity, And Inclusion With Equitable Cancer Care Delivery

Jacquelyne Gaddy, MD, MSc

[Learn More](#)

Cancer Genetics and Prevention Seminar

December 16; 2:30 PM

Increasing Uptake of Genetic Testing for Eligible Cancer Patients-The Michigan

Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24)

Through this FOA, the NCI solicits applications from institutions/organizations to participate in the Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network. The 'CASCADE' Network will conduct pragmatic clinical trials evaluating the effectiveness of clinically proven interventions to overcome barriers and reduce failures in the cervical cancer screening, management, and precancer treatment cascade for women living with HIV.

Application Deadline: December 28, 2021

Read More

Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1)

As an integral part of this Cooperative Agreement-funded network, this FOA will (i) provide scientific and statistical leadership for developing network clinical trials concepts and protocols, overseeing their conduct, and analyzing and publishing their results, (ii) ensure compliance with human research participant protection and other regulatory and administrative reporting requirements, and (iii) work towards creating opportunities for training emerging investigators.

Application Deadline: December 28, 2021

Read More

Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1)

As an integral part of this Cooperative Agreement-funded network, this FOA will provide a pluripotent infrastructure for accruing participants to network clinical trials, interface with the UG1 Research Bases and U24 Network Coordinating Center during concept and protocol development to provide insights and input on clinical significance and study feasibility and provide on-site operational leadership for the successful conduct of the network clinical trials.

Application Deadline: December 28, 2021

Read More

Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program Scholar Awards

We are pleased to solicit applications for the Yale Cancer Center (YCC) K12 Calabresi Immuno-Oncology Training Program (IOTP) Scholar Award for junior faculty to enhance research skills beyond the training provided during graduate and postgraduate training.

Application Deadline: January 3, 2022

Read More

YCC Cancer Microbiome Pilot Grants

Thanks to the generosity of a private donor, YCC seeks to fund early-stage laboratory investigations that will advance our understanding of the host microbiome and microbial niches in cancer progression and therapy. Cancer associated microorganisms include bacteria, viruses, fungi, and parasites.

Application Deadline: January 3, 2021

Read More

Mary Kay Ash Foundation Cancer Research Grant

MIGHT Study

Elena Stoffel, MD, MPH

Learn More

Center for GI Cancers Weekly Seminar

December 16; 4:15 PM

"Liquid biopsies": Assessment of Circulating Tumor DNA And Circulating Tumor Cells In Patients With GI Malignancies

Pashtoon Murtaza Kasi, MD, MS

Learn More

Digestive Health Virtual CME Series 2021

December 16; 5:00 PM

Hernia

Andrew Duffy, MD, FACS, FASMBS

Learn More

Submissions

Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications

This grant focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others).

Internal Deadline: January 3, 2021

Read More

Brain Research Foundation: Brain Research Foundation Seed Grant Program 2022

The objective of the BRF Seed Grant Program is to support new and innovative projects, especially those of junior faculty, who are working in new research directions. BRF Seed Grant awards are not intended to supplement existing grants.

Application Deadline: January 4, 2021

Read More

AACR Cancer Disparities Research Fellowships

These represent an effort to encourage and support postdoctoral or clinical research fellows to conduct cancer disparities research and to establish a successful career path in this field. The research proposed for funding may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to cancer disparities.

Application Deadline: January 7, 2022

Read More

CDA for Inclusion and Diversity in Breast Cancer Research

Designed with the primary goal of increasing diversity in the oncology workforce and cancer research. This CDA will provide funding to clinical investigators who have received their initial faculty appointment and identify as members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research.

Application Deadline: January 10, 2022

Read More

YIA for Diversity and Inclusion in Breast Cancer Research

Provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this grant is to fund physicians during the transition from a fellowship program to a faculty appointment.

Application Deadline: January 10, 2022

Read More

HESI THRIVE

THRIVE, a partner in the 2018 Biden Cancer Initiative, provides seed grants for nonclinical, clinical, and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. THRIVE also supports the development of approaches to avoid or lessen these effects.

Letter of Intent Due: January 10, 2022

Read More

Bladder Cancer Research Innovation Awards

This award supports experienced investigators with exceptionally novel and creative projects designed to produce significant advances in our understanding of the management of bladder cancer. The proposed research may be basic, translational, clinical or epidemiological and must have direct applicability and relevance to bladder cancer. Applications must include

innovative approaches and new ideas to be eligible for funding.

Application Deadline: January 12, 2022

Read More

Susan D. Flynn Oncology Nursing Fellowship at Smilow Cancer Hospital

The Susan D. Flynn Oncology Nursing Fellowship Program at Smilow Cancer Hospital is intended to help stimulate the career interest and foster the professional development of future oncology nurses. Since 2014, Greenwich Hospital has been home to the Fellowship, but this year the program will be expanded to Smilow Cancer Hospital in New Haven as well. Six undergraduate nursing students enrolled in a BSN program who have just completed their junior year will be chosen for an immersive 8-week experience in oncology nursing; two at Greenwich Hospital and four in New Haven.

The fellowship will enhance the student's core clinical education through direct observation and exposure to oncology nursing care. Through this experience, students will learn about the various oncology nursing roles and responsibilities and discover possible career opportunities.

Application Deadline: January 14, 2022. Applications should be sent to: kristina.capretti@greenwichhospital.org

<http://sdfondp.com/>

The Jackson Laboratory – Yale Cancer Center Joint Pilot Project Grant: Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis

The pilot funding will support innovative cancer research on the topic of "Deciphering the Tumor Microenvironment Using Advanced Imaging and Analysis." Proposals may be focused on spatial data analysis, technology investigation, or hypothesis-based research making innovative use of advanced imaging techniques.

Proposals are due by: January 14, 2022. Email your application to jaxccadmin@jax.org

Read More

BMSF Diversity in Clinical Trials Career Development Program

The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.

Application Deadline: January 14, 2022

Read More

ASCO Medical Student Rotation for Underrepresented Populations

Provides financial support for U.S. medical students from populations underrepresented in medicine and who are interested in oncology as a career to experience a minimum 4-week clinical or clinical research rotation.

Application Deadline: January 25, 2022

Read More

ASCO Diversity Mentoring Program

Designed to encourage U.S. based medical students and residents who are underrepresented in medicine to pursue rewarding careers in oncology by pairing with a mentor.

Application Deadline: January 25, 2022

Read More

BMSF Clinical Investigator Pipeline Program

This Program was established to build the pipeline of community oriented clinical trialists of diverse backgrounds who are committed to increasing diversity, equity and inclusion in clinical trials. This will be a 6-week summer externship program for 250 underrepresented medical students, and with hands-on community-oriented clinical trial experience in underserved communities.

Application Deadline: January 28th, 2022

Read More

Leslie Warner Postdoctoral Fellowships for Cancer Research

The Fellowships will support early-stage promising trainees that are conducting innovative basic, translational, clinical, or population-based cancer research with a Yale Cancer Center member. Relevance of proposed research to our catchment area priorities is also encouraged. Candidates may have up to one year of postdoctoral experience from the time of application.

Internal Deadline: February 1, 2022

Read More

Leukemia Research Foundation Grant

The application process for the 2022-2023 funding cycle has begun! Grants of up to \$100K are available to new investigators -- researchers within seven years of their first independent faculty-level position. Research projects must focus on a blood cancer (leukemia, lymphoma, myeloma, or MDS).

Letter of Intent Due: February 4, 2022

Read More

Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01, R21)

The purpose of this FOA is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.

Application Deadline: February 5, 2022

Read More

Early K99/R00 Funding Opportunity Announcements

The NCI just reissued "early K99/R00" - NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers FOAs that might be of interest to some postdoctoral fellows.

- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

Application Deadlines: February 28, 2022

Read More

NCI Pathway to Independence Award for Outstanding Early Stage

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)

The purpose of this award is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions.

Application Deadline: February 28, 2022

Read More

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

Application Deadline: February 28, 2022

Read More

DeLuca Career Development Award 2022

The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the ultimate goal to achieve independent support for their research from a national agency. For further information contact Richard.Carr@yale.edu

Letter of Intent Due: March 1, 2022

Read More